Veterinary Medicines

Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable pour chiens

Authorised
  • Canine distemper virus, strain N-CDV, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
Download as PDF

Product identification

Medicine name:
Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable pour chiens
Vanguard DA2PI-CPV Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Canine distemper virus, strain N-CDV, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain N-CDV, Live
    3.00
    log10 50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    7.00
    log10 50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    3.20
    log10 50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    6.00
    log10 50% cell culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Available in:
  • Luxembourg
Package description:
  • Vanguard DA2PI-CPV 1 dose Vial Lyophilisate and solvent for suspension for injection
  • Vanguard DA2PI-CPV 10 1 dose Vial Lyophilisate and solvent for suspension for injection
  • Vanguard DA2PI-CPV 100 1 dose Vial Lyophilisate and solvent for suspension for injection
  • Vanguard DA2PI-CPV 25 1 dose Vial Lyophilisate and solvent for suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Ministry Of Health And Social Security
Authorisation number:
  • V 087/93/11/0351
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 16/01/2024
Download